《新股表現》荃信生物-B(02509.HK)暗盤現報26.9元 高上市價近36%
根據輝立交易場,將於明日掛牌的荃信生物-B(02509.HK)暗盤開報26元,較上市價19.8元,高31%;現報26.9元,高上市價35.9%,成交23.8萬股,涉資658萬元。
荃信生物-B為內地針對自身免疫及過敏性疾病生物療法的臨床階段生物科技商,全球發售1,204.64萬股,香港公開發售佔約一成,國際發售佔九成。招股價範圍介乎每股19.8至20.2元。公司上市引入3名基石投資者,包括股東泰州健鑫旗下健鑫醫藥、華東醫藥(000963.SZ)旗下華東投資及蜂投資本,合共認購2,500萬美元公司股份。獨家保薦人為中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.